Skip Navigation
Menu
ACP Journal Club |20 November 2018

In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not

John K. Marshall, MD, MSc, FRCPC, AGAF

Article, Author, and Disclosure Information
FULL TEXT
Jankowski JA, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392:400-8. 30057104

GIM/FP/GP:

Gastroenterology:

In Barrett esophagus (BE), does high- vs low-dose esomeprazole and aspirin vs no aspirin reduce all-cause mortality, esophageal adenocarcinoma, and high-grade dysplasia?
Randomized controlled 2 x 2 factorial trial (Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia Trial [AspECT]). EudraCT 2004-003836-77.
Concealed.*
Blinded* {pathologists evaluating adenocarcinoma and dysplasia outcomes}†.
Maximum 10 years (median 8.9 y).
84 centers in the UK and 1 center in Canada.
2557 patients ≥ 18 years of age (median age 59 y,...
FULL TEXT
PDF
Not Available
Citations
Citation

Marshall JK. In Barrett esophagus, high- vs low-dose esomeprazole improved clinical outcomes; aspirin vs no aspirin did not. Ann Intern Med. 2018;169:JC54. doi: 10.7326/ACPJC-2018-169-10-054

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2018;169(10):JC54.

DOI: 10.7326/ACPJC-2018-169-10-054

©
2018 American College of Physicians
0 Citations

Related Articles
Update in Gastroenterology and Hepatology
Annals of Internal Medicine; 145 (4): 294-298
Update in Gastroenterology and Hepatology: Evidence Published in 2011
Annals of Internal Medicine; 157 (1): 44-48
Update in Gastroenterology and Hepatology
Annals of Internal Medicine; 141 (5): 374-380
Update in Hospital Medicine
Annals of Internal Medicine; 145 (9): 685-691
View MoreView Less

Journal Club
In HF with secondary mitral regurgitation, percutaneous mitral valve repair did not improve 1-year clinical outcomes
Annals of Internal Medicine; 170 (2): JC8
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events
Annals of Internal Medicine; 167 (6): JC28
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
Annals of Internal Medicine; 169 (12): JC67
In embolic stroke of undetermined source, rivaroxaban vs aspirin did not reduce recurrence and increased bleeding
Annals of Internal Medicine; 169 (6): JC32
View MoreView Less

Related Topics
Esophageal Disorders
Gastroenterology/Hepatology

Esophageal Disorders, Gastroenterology/Hepatology.

PubMed Articles
Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder.
Neuropsychobiology 2019.
Long-Term Effect of Different Optimizing Methods for Cardiac Resynchronization Therapy in Patients with Heart Failure: A Randomized and Controlled Pilot Study.
Cardiology 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×